Jia Li1, Stuart C Gordon2, Loralee B Rupp3, Talan Zhang1, Sheri Trudeau1, Scott D Holmberg4, Anne C Moorman4, Philip R Spradling4, Eyasu H Teshale4, Joseph A Boscarino5, Mark A Schmidt6, Yihe G Daida7, Mei Lu1. 1. Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan. 2. Division of Gastroenterology and Hepatology, Henry Ford Health System and Wayne State University School of Medicine, Detroit, Michigan. 3. Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan. 4. Division of Viral Hepatitis, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Department of Epidemiology & Health Services Research, Geisinger Clinic, Danville, Pennsylvania. 6. Center for Health Research, Kaiser Permanente-Northwest, Portland, Oregon. 7. Center for Health Research, Kaiser Permanente-Hawai'i, Honolulu, Hawaii.
Abstract
BACKGROUND: Sustained virological response to treatment for chronic hepatitis C virus may improve short-term glucose control among patients with type 2 diabetes, but the long-term impact remains largely unknown. We used data from the Chronic Hepatitis Cohort Study to investigate the impact of sustained virological response on long-term trends in haemoglobin A1c in patients with type 2 diabetes. METHODS: "Index date" was defined as the date of treatment initiation (treated patients) or hepatitis C virus diagnosis (untreated patients). To address treatment selection bias, we used a propensity score approach. We used a piecewise, linear spline, mixed-effects model to evaluate changes in haemoglobin A1c over a 5-year period. RESULTS: Our sample included 384 hepatitis C virus patients with type 2 diabetes (192 untreated, 192 treated, with sustained virological response or treatment failure). After adjusting for body mass index, haemoglobin A1c was stable among untreated and treatment failure patients. In sustained virological response patients, Hb1Ac trajectories evolved in three phases: (a) index through 6 months post-index, average haemoglobin A1c decreased significantly from 7.7% to 5.4% per 90 days (P < 0.001); (b) 6-30 months post-index, haemoglobin A1c rebounded at a rate of 1.5% every 90 days (P = 0.003); and (c) from 30 months onward, haemoglobin A1c stabilized at an average level of 7.9 (P-value = 0.34). Results from an analysis restricted to patients receiving direct-acting antivirals were consistent with the main findings. CONCLUSION: Successful hepatitis C virus treatment among patients with type 2 diabetes significantly reduces HbA1c shortly after treatment, but these decreases are not sustained long-term. Less than three years after sustained virological response, haemoglobin A1c rebounds to levels similar to untreated/treatment failure patients, and higher than recommended for type 2 diabetic maintenance.
BACKGROUND: Sustained virological response to treatment for chronic hepatitis C virus may improve short-term glucose control among patients with type 2 diabetes, but the long-term impact remains largely unknown. We used data from the Chronic Hepatitis Cohort Study to investigate the impact of sustained virological response on long-term trends in haemoglobin A1c in patients with type 2 diabetes. METHODS: "Index date" was defined as the date of treatment initiation (treated patients) or hepatitis C virus diagnosis (untreated patients). To address treatment selection bias, we used a propensity score approach. We used a piecewise, linear spline, mixed-effects model to evaluate changes in haemoglobin A1c over a 5-year period. RESULTS: Our sample included 384 hepatitis C viruspatients with type 2 diabetes (192 untreated, 192 treated, with sustained virological response or treatment failure). After adjusting for body mass index, haemoglobin A1c was stable among untreated and treatment failurepatients. In sustained virological response patients, Hb1Ac trajectories evolved in three phases: (a) index through 6 months post-index, average haemoglobin A1c decreased significantly from 7.7% to 5.4% per 90 days (P < 0.001); (b) 6-30 months post-index, haemoglobin A1c rebounded at a rate of 1.5% every 90 days (P = 0.003); and (c) from 30 months onward, haemoglobin A1c stabilized at an average level of 7.9 (P-value = 0.34). Results from an analysis restricted to patients receiving direct-acting antivirals were consistent with the main findings. CONCLUSION: Successful hepatitis C virus treatment among patients with type 2 diabetes significantly reduces HbA1c shortly after treatment, but these decreases are not sustained long-term. Less than three years after sustained virological response, haemoglobin A1c rebounds to levels similar to untreated/treatment failurepatients, and higher than recommended for type 2 diabetic maintenance.
Authors: Francesco Negro; Daniel Forton; Antonio Craxì; Mark S Sulkowski; Jordan J Feld; Michael P Manns Journal: Gastroenterology Date: 2015-08-28 Impact factor: 22.682
Authors: M Sanni Ali; Rolf H H Groenwold; Svetlana V Belitser; Wiebe R Pestman; Arno W Hoes; Kit C B Roes; Anthonius de Boer; Olaf H Klungel Journal: J Clin Epidemiol Date: 2014-11-26 Impact factor: 6.437
Authors: Anne C Moorman; Stuart C Gordon; Loralee B Rupp; Philip R Spradling; Eyasu H Teshale; Mei Lu; David R Nerenz; Cynthia C Nakasato; Joseph A Boscarino; Emily M Henkle; Nancy J Oja-Tebbe; Jian Xing; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2012-09-18 Impact factor: 9.079
Authors: J Li; S C Gordon; L B Rupp; T Zhang; J A Boscarino; V Vijayadeva; M A Schmidt; M Lu Journal: J Viral Hepat Date: 2014-01-29 Impact factor: 3.728
Authors: Diego Casas-Deza; Ana Martínez-Sapiña; Silvia Espina; Beatriz Garcia-Rodriguez; Eva M Fernandez-Bonilla; Alejandro Sanz-Paris; Yolanda Gonzalez-Irazabal; Vanesa Bernal-Monterde; Jose M Arbones-Mainar Journal: J Clin Med Date: 2022-07-13 Impact factor: 4.964
Authors: Pradeep Kumar Mada; Matthew E Malus; Arvin Parvathaneni; Bing Chen; Gabriel Castano; Sharon Adley; Maureen Moore; Michinari Hieda; Mohammed J Alam; Mark Feldman; John William King Journal: Int J Hepatol Date: 2020-01-13